JP2010501572A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501572A5
JP2010501572A5 JP2009525631A JP2009525631A JP2010501572A5 JP 2010501572 A5 JP2010501572 A5 JP 2010501572A5 JP 2009525631 A JP2009525631 A JP 2009525631A JP 2009525631 A JP2009525631 A JP 2009525631A JP 2010501572 A5 JP2010501572 A5 JP 2010501572A5
Authority
JP
Japan
Prior art keywords
cancer
compound according
deuterium
formulation
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501572A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/018655 external-priority patent/WO2008024439A2/en
Publication of JP2010501572A publication Critical patent/JP2010501572A/ja
Publication of JP2010501572A5 publication Critical patent/JP2010501572A5/ja
Pending legal-status Critical Current

Links

JP2009525631A 2006-08-22 2007-08-22 ４−アミノキナゾリン誘導体およびその使用方法 Pending JP2010501572A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83950306P 2006-08-22 2006-08-22
PCT/US2007/018655 WO2008024439A2 (en) 2006-08-22 2007-08-22 4-aminoquinazoline derivatives and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2010501572A JP2010501572A (ja) 2010-01-21
JP2010501572A5 true JP2010501572A5 (enExample) 2010-09-30

Family

ID=39107412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525631A Pending JP2010501572A (ja) 2006-08-22 2007-08-22 ４−アミノキナゾリン誘導体およびその使用方法

Country Status (9)

Country Link
US (2) US20080051422A1 (enExample)
EP (1) EP2054063A4 (enExample)
JP (1) JP2010501572A (enExample)
KR (1) KR20090042994A (enExample)
CN (1) CN101594870A (enExample)
AU (1) AU2007288204A1 (enExample)
CA (1) CA2661223A1 (enExample)
MX (1) MX2009001814A (enExample)
WO (1) WO2008024439A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
US8604044B2 (en) * 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
US20090215802A1 (en) * 2007-09-13 2009-08-27 Protia, Llc Deuterium-enriched lapatinib
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
JP2011516426A (ja) * 2008-03-28 2011-05-26 コンサート ファーマシューティカルズ インコーポレイテッド キナゾリン誘導体および治療方法
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
ES2451542T3 (es) * 2008-08-29 2014-03-27 Concert Pharmaceuticals Inc. Derivados de triazolo-piridazina sustituidos
US8541419B2 (en) * 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
MX2011002033A (es) * 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
CN101735200B (zh) * 2008-11-17 2013-01-02 岑均达 喹唑啉类化合物
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
CA2775601C (en) 2009-09-28 2017-10-03 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
US20110195066A1 (en) * 2010-02-05 2011-08-11 Auspex Pharmaceuticals, Inc. Quinoline inhibitors of tyrosine kinase
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
CN102453025B (zh) * 2010-10-18 2014-08-13 齐鲁制药有限公司 拉帕替尼中间体晶型及其制备方法
EP2654754B1 (en) * 2010-12-17 2016-12-21 Novartis AG Combination for treating osteosarcoma, rhabdomyosarcoma and neuroblastoma
CN102321076B (zh) * 2011-07-07 2013-08-21 中国科学技术大学 拉帕替尼中间体及其类似物的制备方法
CN102659764A (zh) * 2012-04-16 2012-09-12 中国科学院广州生物医药与健康研究院 酪氨酸激酶不可逆抑制剂及其制备方法和用途
CZ2012712A3 (cs) 2012-10-17 2014-04-30 Zentiva, K.S. Nový způsob výroby klíčového intermediátu výroby lapatinibu
CN102911164A (zh) * 2012-11-07 2013-02-06 江苏金桥盐化集团利海化工有限公司 一种拉帕替尼关键中间体的制备方法
ITVI20130003A1 (it) * 2013-01-14 2014-07-14 F I S Fabbrica Italiana Sint I S P A Procedimento per la preparazione di lapatinib e suoi sali mediante nuovi intermedi.
US9024023B2 (en) 2013-01-14 2015-05-05 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates
CN104513231A (zh) * 2015-01-09 2015-04-15 安润医药科技（苏州）有限公司 拉帕替尼及其中间体的合成方法
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
US20200290978A1 (en) * 2017-09-26 2020-09-17 The Regents Of The University Of California Compositions and methods for treating cancer
CN107827877B (zh) * 2017-11-21 2021-05-07 陕西师范大学 二烷基氨基喹唑啉类化合物及其在制备抗肿瘤药物中的应用
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
CN108187055B (zh) * 2018-03-06 2019-12-27 北京大学 一种具有协同增效作用的抗癌组合物
CN108690001A (zh) * 2018-06-26 2018-10-23 苏州市贝克生物科技有限公司 拉帕替尼类似物的合成
EP4405360A4 (en) 2021-09-23 2025-08-20 Erasca Inc POLYMORPHIC FORMS OF EGFR INHIBITOR

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69716916T2 (de) * 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1660486A4 (en) * 2003-08-08 2006-12-13 Ulysses Pharmaceutical Product HALOGENATED CHINAZOLINYL NITROFURANES AS ANTIBACTERIAL AGENTS
WO2005046678A1 (en) * 2003-11-07 2005-05-26 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2005251722B2 (en) * 2004-06-03 2009-11-12 Smithkline Beecham (Cork) Limited Cancer treatment method
JP2008501708A (ja) * 2004-06-04 2008-01-24 スミスクライン ビーチャム （コーク） リミテッド がんの治療方法
CA2571421A1 (en) * 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20090215802A1 (en) * 2007-09-13 2009-08-27 Protia, Llc Deuterium-enriched lapatinib
WO2010005585A2 (en) * 2008-07-09 2010-01-14 Concert Pharmaceuticals Inc. 4-aminoquinazoline prodrugs

Similar Documents

Publication Publication Date Title
JP2013518089A5 (enExample)
JP2022071077A5 (enExample)
CN115803325A (zh) 一种egfr抑制剂及其制备方法和应用
JP2022017295A5 (enExample)
JP2017537080A5 (enExample)
ME00937B (me) Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera
JP2012153722A5 (enExample)
NZ561609A (en) 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
NZ587504A (en) Benzopyrazole derivatives as ERK inhibitors
JP2013512263A5 (enExample)
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2008505167A5 (enExample)
IL266563B (en) Heterocyclic compounds useful as pdk1 inhibitors
EA201170627A1 (ru) Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности
MX2014013367A (es) Composiciones organicas para tratar enfermedades relacionadas con kras.
MX2009011343A (es) Inhibidores quinasa utiles para el tratamiento de enfermedades mieloproliferativas y otras enfermedades proliferativas.
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
JP2013166763A5 (enExample)
HK1246645A1 (zh) 细胞周期蛋白依赖性激酶的抑制剂
JP2016503414A5 (enExample)
MY189345A (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
WO2017044858A3 (en) Inhibitors of cyclin-dependent kinases
JP2017036314A5 (enExample)
GEP201706678B (en) Method of treating cancer and bone cancer
JP2017526662A5 (enExample)